Compare Novartis AG (NVS) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs SYSCO Corporation — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while SYSCO Corporation trades at $81.33 (market cap $38.63B). The key difference: Novartis AG is far larger — about 7.5× SYSCO Corporation's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | SYY | |
|---|---|---|
Market Cap | $290.25B | $38.63B |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $91.16 |
52-Week Low | $113.50 | $69.30 |
Enterprise Value | $330.27B | $52.11B |
Dividend Yield | 3.17% | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
SYY trades at $81.22, down 0.58% on the day, with a bullish technical signal supported by moving averages. The company reported mixed Q1 2026 earnings, missing EPS expectations of $0.945 with $0.94, but maintains strong revenue growth, reaching $81.37B in 2025. Analyst consensus is bullish with a $84.75 price target, and the upcoming Q4 2026 earnings report on August 4 is a key catalyst. Recent news highlights operational efficiency gains and AI integration, including a Newsweek AI Impact Award.
SYY presents a moderate buy opportunity with upside to the consensus target, supported by stable cash flow and dividend payments. Risks include thin net margins of 2.08% and elevated debt levels, with long-term debt at $11.51B. The stock's valuation is reasonable with a P/E of 22.44, but margin pressure and economic sensitivity in the food distribution sector warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
